Prescription Carvedilol recalled for manufacturing impurity exceeding FDA specifications
Glenmark Pharmaceuticals is recalling Carvedilol 25 mg tablets nationwide due to a manufacturing quality issue with impurity levels exceeding FDA recommended limits. Multiple lot numbers and expiration dates from February 2025 through February 2026 are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves manufacturing quality deviation with N-Nitroso Carvedilol I impurity exceeding FDA recommended limits. Per the severity rubric, this is a risk-of-harm scenario, placing it in severity 3 (High).
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Carvedilol 25 mg tablets (NDC 68462-165-05 and 68462-165-01) due to a manufacturing quality deviation identified during testing. The N-Nitroso Carvedilol I (NNCI-I) impurity levels in affected batches exceed the FDA recommended limit.
The recall affects multiple lot numbers that were distributed nationwide in the United States. The affected products have expiration dates from February 2025 through February 2026. This is classified as a Class II recall by the FDA.
Patients currently using Carvedilol tablets should contact their pharmacist or healthcare provider to verify whether their medication is included in this recall. The FDA has published specific lot numbers and expiration dates to help identify affected products.
The recalled product
- Product
- CARVEDILOL (CARVEDILOL)
- Brand
- CARVEDILOL
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot numbers: a) 17230500
- 17230509
- 17230526
- 17230546
- 17230551
- 17230603
- 17230628
- 17230642
- 17230645
- 17230681
- Exp.:02/2025
- 17230829
- 17230832
- 17230854
- 17230864
- 17230874
- 17230876
- 17230889
- 17230894
- Exp.: 03/2025
UPCs (5)
- 0368462162019
- 0368462163016
- 0368462164013
- 0368462165010
- 202517231315
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · CARVEDILOL
- HighMajor Pharmaceuticals carvedilol tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-27
- HighCarvedilol 12.5 mg tablets recalled over nitrosamine above acceptable intake level
FDA (Drugs) · 2025-08-20
- HighCarvedilol 3.125 mg tablets recalled for nitrosamine impurity above intake limit
FDA (Drugs) · 2025-08-20
- HighGlenmark carvedilol 25 mg tablets exceed the acceptable nitrosamine intake level
FDA (Drugs) · 2025-08-20
- HighGlenmark carvedilol 12.5 mg tablets exceed the nitrosamine impurity limit
FDA (Drugs) · 2025-08-20
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · n nitroso impurity
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11